EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

BRAF V600E/ RAS Mutations and Lynch Syndrome in Patients With MSI-H/dMMR Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors

Raphael Colle, Sara Lonardi, Marine Cachanado iD, Michael J Overman, Elena Elez iD, Marwan Fakih iD, Francesca Corti, Priya Jayachandran, Magali Svrcek, Antoine Dardenne, Baptiste Cervantes, Alex Duval und 3 weitere

The Oncologist · 2023

DOI: 10.1093/oncolo/oyad082 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, 2023. Verfasst von Raphael Colle und 14 weiteren Autor:innen. Beteiligte Einrichtung: Sorbonne University, Department of Medical Oncology, Saint-Antoine Hospital, AP-HP, Paris, France. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Hereditary Nonpolyposis, Colonic Neoplasms, Colorectal Neoplasms. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Association de Recherche en Oncologie Saint-Antoine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We pooled data from 2 cohorts of immune checkpoint inhibitors-treated microsatellite instability-high/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer patients to evaluate the prognostic value of RAS/BRAFV600E mutations and Lynch syndrome (LS). Patients and Methods Patients were defined as LS-linked if germline mutation was detected and as sporadic if loss of MLH1/PMS2 expression with BRAFV600E mutation and/or MLH1 promoter hypermethylation, or biallelic somatic MMR genes mutations were found. Progression-free survival (PFS) and overall survival (OS) were adjusted on prognostic modifiers selected on unadjusted analysis (P < .2) if limited number of events.

Results

Of 466 included patients, 305 (65.4%) and 161 (34.5%) received, respectively, anti-PD1 alone and anti-PD1+anti-CTLA4 in the total population, 111 (24.0%) were treated in first-line; 129 (28.8%) were BRAFV600E-mutated and 153 (32.8%) RAS-mutated. Median follow-up was 20.9 months. In adjusted analysis of the whole population (PFS/OS events = 186/133), no associations with PFS and OS were observed for BRAFV600E-mutated (PFS HR= 1.20, P = .372; OS HR = 1.06, P = .811) and RAS-mutated patients (PFS HR = 0.93, P = .712, OS HR = 0.75, P = .202). In adjusted analysis in the Lynch/sporadic status-assigned population (n = 242; PFS/OS events = 80/54), LS-liked patients had an improved PFS compared to sporadic cases (HR = 0.49, P = .036). The adjusted HR for OS was 0.56 with no significance (P = .143). No adjustment on BRAFV600E mutation was done due to collinearity.

Conclusion

In this cohort, RAS/BRAFV600E mutations were not associated with survival while LS conferred an improved PFS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal Neoplasms, Hereditary NonpolyposisColonic NeoplasmsColorectal NeoplasmsBrain NeoplasmsNeoplastic Syndromes, HereditaryMutationProto-Oncogene Proteins B-rafHumansMicrosatellite InstabilityImmune Checkpoint InhibitorsDNA Mismatch Repair

Stichwörter der Autor:innen

BRAF mutationRAS mutationLynch syndromedeficient mismatch repairimmune checkpoint inhibitorsmetastatic colorectal cancer

Substanzen

Proto-Oncogene Proteins B-rafImmune Checkpoint InhibitorsBRAF protein, human

Autor:innen und Institutionen

  • Sorbonne University, Department of Medical Oncology, Saint-Antoine Hospital, AP-HP, Paris, France.
  • Sorbonne University, SIRIC CURAMUS, INSERM, Unité Mixte de Recherche Scientifique 938, Centre de Recherche Saint-Antoine, Equipe Instabilité des Microsatellites et Cancer, Equipe Labellisée par la Ligue Nationale Contre…
  • Sorbonne University, Department of Clinical Pharmacology and Clinical Research Platform Paris-East (URCEST-CRC-CRB), Assistance Publique-Hôpitaux de Paris, Sorbonne University, St Antoine Hospital, Paris, France.
  • Oncology Department, Istituto Oncologico Veneto IOV-IRCSS, Padua, Italy.
  • Department of Gastrointestinal Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Department of Medical Oncology, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autonoma de Barcelona, Barcelona, Spain.

ORCID-Profile: Marine Cachanado, Elena Elez, Marwan Fakih, Romain Cohen, Filippo Pietrantonio, Thierry André

Förderung

  • Association de Recherche en Oncologie Saint-Antoine

Zitieren

APA

Colle, R., Lonardi, S., Cachanado, M., Overman, M. J., Elez, E., Fakih, M., Corti, F., Jayachandran, P., Svrcek, M., Dardenne, A., Cervantes, B., Duval, A., Cohen, R., Pietrantonio, F., & André, T. (2023). BRAF V600E/ RAS Mutations and Lynch Syndrome in Patients With MSI-H/dMMR Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors. The Oncologist. https://doi.org/10.1093/oncolo/oyad082

Vancouver

Colle R, Lonardi S, Cachanado M, Overman MJ, Elez E, Fakih M, et al. BRAF V600E/ RAS Mutations and Lynch Syndrome in Patients With MSI-H/dMMR Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors. The Oncologist. 2023. doi:10.1093/oncolo/oyad082

BibTeX
@article{Colle2023,
  author = {Colle, Raphael and Lonardi, Sara and Cachanado, Marine and Overman, Michael J and Elez, Elena and Fakih, Marwan and Corti, Francesca and Jayachandran, Priya and Svrcek, Magali and Dardenne, Antoine and Cervantes, Baptiste and Duval, Alex and Cohen, Romain and Pietrantonio, Filippo and André, Thierry},
  title = {BRAF V600E/ RAS Mutations and Lynch Syndrome in Patients With MSI-H/dMMR Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors},
  journal = {The Oncologist},
  year = {2023},
  doi = {10.1093/oncolo/oyad082}
}
Kostenlos starten →